Abstract: Disclosed is a composition for treating a joint disease or a connective tissue disease, a composition for cartilage regeneration, or a composition for treating an inflammatory disease, each of the compositions containing dextran, poloxamer or a mixture thereof. The composition stays in the joint or connective tissue for a long time due to the shock-absorbing effect, coating effect or anti-inflammation effect, relieves the shock, covers a damaged portion in a specific manner thereto, or reduces inflammation of an adhered portion. Thus, the composition may be useful for the treatment of the joint disease, the connective tissue disease, or for the cartilage regeneration.

Abstract: The present invention provides a branched poly(amino acid) antimicrobial agent, comprising a branched poly(amino acid); the branched poly(amino acid) is obtained by the homopolymerization of one amino acid unit, or is obtained by the copolymerization of two or more amino acid units; the amino acid unit has a structure shown by Formula I. The present invention uses the amino acid as raw material, is non-toxic, has no side effects, and is a green and environmentally friendly new antimicrobial agent, and accessible to the users. The branched structure of the poly(amino acid) results in that such material has many active functional groups, may be further modified, has good biocompatibility, and will not develop drug resistance during the long-term use of this antimicrobial agent.

Abstract: A method of modulating oxygen saturation levels can include measuring oxygen saturation levels in a patient, administering inhaled nitric oxide, adjusting the dose of oxygen in real time to a second dose based on the inhaled nitric oxide.

Abstract: This application provides a composition for ameliorating a post-cerebral stroke sequela in a human, comprising molecular hydrogen as an active ingredient, and a method for ameliorating a post-cerebral stroke sequela, comprising administering the composition to a human having a post-cerebral stroke sequela.

Abstract: An object of the present invention is to provide a highly effective method for treatment/remission of cancer, and prevention of recurrence/metastasis of cancer at low cost and with few side effects. A composition containing a urinary alkalinization agent, for use in treatment or remission of cancer, or prevention of recurrence or metastasis of cancer.

Abstract: Methods for treatment of a multi-drug resistant (MDR) tumor in a subject are disclosed. The methods comprise administering to the subject in need of treatment a therapeutically effective amount of an anti-mycoplasma agent and/or an agent blocking the interaction between membrane protein P37 of mycoplasma and Annexin A2 of host cells of the subject, prior to, at the same time with, or after chemotherapy. Relevant pharmaceutical compositions, kits, uses are also disclosed.

Abstract: In one embodiment, a composition is provided, comprising: 0.0005 wt % to 0.05 wt % of silver composition, based on a total weight of the composition; 0.01 wt % to 1.0 wt % of hyaluronic acid, based on the total weight of the composition; and 0.05 wt % to 2.5 wt % of allantoin, based on the total weight of the composition. In one embodiment, a method of treating a skin wound is provided, comprising: topically applying a sufficient amount of a composition to the skin wound of a patient to cover the skin wound, the composition comprising: 0.0005 wt % to 0.05 wt % of silver composition, based on a total weight of the composition; 0.01 wt % to 0.1 wt % of hyaluronic acid, based on the total weight of the composition; and 0.05 wt % to 2.5 wt % of allantoin, based on the total weight of the composition.

Abstract: The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders.

Abstract: The present invention provides a protein, in particular a TCR comprising a V? amino acid sequence with a sequence identity of at 90%, to a sequence selected from SEQ ID NO: 1 to 27, a T-cell comprising the TCR a method of selecting a T-cell product for use in active immunotherapy based on the identification of an V? amino acid sequence with a sequence identity of at 90%, to a sequence selected from SEQ ID NO: 1 to 27 in a T-cell product.

Abstract: Described herein are compositions and methods of treatment for identifying and clearing cell types expressing particular cell surface markers. In one embodiment, the composition comprises a polypeptide construct that selectively binds a J-configuration of CD277 on a target cell, wherein said polypeptide construct is expressed in an engineered cell.

Abstract: The present disclosure provides mammalian cells such as regulatory T cells containing a transgene in the FOXP3 genomic locus. Also provided are methods of generating the cells and methods of using the cells to treat patients in need of immunosuppression.

Abstract: Described herein are methods and compositions useful for augmenting cell-based immunotherapies. The augmented cell-based immunotherapies can be used to treat individuals with cancer and chronic viral infections.

Abstract: An NK cell with low SMAD3 expression and altered gene expression profile resulting in high cytokine expression and TGF-? superfamily resistance is described, refered to herein as TGF-? superfamily-imprinted Natural Killer Cells (TGF?i NK cells). A method of treating cancer or infection in a subject in need thereof is described. The method includes administering a therapeutically effective number of TGF?i NK cells to the subject. A method of producing TGF?i NK cells is described by in vitro activation of natural killer cells in the presence of a TGF-? superfamily cytokine.

Abstract: The invention features methods of producing compositions enriched in Tregs and methods for treating immunological disorders using these compositions. The invention also features methods for producing compositions enriched in lymphocytes and depleted of Tregs and the use of these compositions in the treatment of proliferative disorders.

Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.

Abstract: Disclosed are angiopoietin-1 (Ang-1)- or VEGF-secreting stem cells promotive of vascular formation, a generation method therefor, and a use thereof in preventing or treating cardiovascular disease.

Abstract: Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.

Abstract: Disclosed herein are method of treating hemophilia A in a subject comprising injecting the subject with mesenchymal stromal/stem cells (MSC) modified to express high levels of Factor VIII protein. The MSC are injected into the subject prenatally. The modified MSC may also express high levels von Willebrand factor protein.

Abstract: Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.

Abstract: A network of neurospheres (NNet) mimicking the small-world hierarchic-modular architecture of mammalian brains, created by synthetically building a network of inter-connected individual brain microphysiological systems (MPSs).

Abstract: Provided herein is a ligament ECM soluble fraction useful for the growth and regrowth of ligament tissue. Methods of preparation of the soluble fractions and use of the soluble fractions in growth or regrowth of ligament tissue also are provided.

Abstract: Disclosed herein are methods and compositions comprising placental adherent stromal cells, conditioned media derived from a cultured placental ASC, lysates thereof, and fractions thereof, for treating a skin condition (e.g. a compromised skin barrier, acne, wrinkles, hyper/hypo-pigmentation, dryness, elastosis); increasing skin volume, and preventing or treating alopecia and related conditions.

Abstract: An object of the present invention is to provide a cell population comprising safe adherent stem cells maintaining a normal karyotype and a method for producing the cell population, and a pharmaceutical composition comprising the cell population. According to the present invention, a production method of a cell population comprising adherent stem cells, comprising obtaining a cell population in which the proportion of KCNAB1-positive adherent stem cells in the cell population is 85% or more, is provided.

Abstract: The invention provides a method for the treatment or prevention of GI tract dysbiosis in a subject, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.

Abstract: Provided herein are compositions, methods, and kits for the treatment of cancer. The disclosure also provides compositions, methods, and kits that suppress adverse events caused by anticancer therapy.

Abstract: An object of the present invention is to provide, when preparing food products for dysphagia patients, a food product for dysphagia patients having useful functions of probiotics and capable of delivering probiotics administered to a dysphagia patient to the intestines as viable cells by imparting functions of probiotics to such food products, and a thickening composition therefor. For achieving these objects, the present invention provides a thickening composition for dysphagia patients prepared as a powder mixture by mixing dried probiotic cells or a dried probiotic cell preparation and one or more polysaccharides selected from the group consisting of polysaccharides consisting of xanthan gum or guar gum and hydrolysates of these polysaccharides, wherein in the powder mixture, the probiotics and the polysaccharides are allowed to coexist in a contact state.

Abstract: The present invention relates to, in part, compositions and methods for delivery of novel mixtures of bacterial strains for maintaining and/or restoring a healthy gut barrier.

Abstract: Bifidobacterium longum strain NCIMB 41676 is useful for improving or sustaining vitality and/or reducing mental fatigue in stressful situations.

Abstract: The disclosure discloses a probiotic mixed preparation with anti-influenza ability and application thereof, and belongs to the technical fields of microorganisms and medicines. The probiotic mixed preparation has anti-influenza effects, which are embodied in: (1) significantly reducing the degree of weight loss of influenza mice; (2) significantly improving the blood indexes of the influenza mice; (3) significantly improving the inflammation status of respiratory tract infections in the influenza mice; (4) significantly reducing the viral load in the lungs of the influenza mice (i.e., significantly inhibiting the replication and multiplication of influenza viruses in the influenza mice); and (5) significantly increasing the expression quantity of antiviral protein MxA in the lungs of the influenza mice. Therefore, the probiotic mixed preparation has great application prospects in preparation of a product for preventing and/or treating atopic dermatitis and even preventing and/or treating influenza.

Abstract: A composition having Lactobacillus Plantarum strain GMNL-662 for promoting bone regrowth is provided. The Lactobacillus Plantarum strain GMNL-662 has an ability to promote the expression of osteogenic genes, inhibit the expression of osteoclast related genes, and promote the expression of osteogenesis-related cytokine TGF-?, so that the bone loss is improved.

Abstract: The present invention provides an intestinal tract protective agent comprising a polyphosphoric acid or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Combination with immune checkpoint inhibitors increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioglastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.

Abstract: The present invention relates to compositions comprising at least about 8% ?-glucans and/or at least about 8% ?-fucans, which has a prebiotic effect and act as a replacement for in-feed antibiotics. The present invention also relates to extraction methods to obtain such extracts and various uses for the compositions comprising ?-glucans and/or ?-fucans.

Abstract: The present invention provides Dunaliella alga, and extracts thereof, comprising increased levels of 9-cis-?-carotene and/or increased levels of colourless carotenoids; and/or increased levels of ?-carotene, to processes for producing such Dunaliella alga, and to uses thereof.

Abstract: A composition comprising at least a mixture of molecules extracted from Chrysanthellum indicum, Cynara scolymus and Lycium barbarum. This composition is in particular useful as a nutritional product or health product to prevent and/or combat fat and/or carbohydrate metabolism disorders in Humans or animals.

Abstract: The present disclosure relates to methods of improving the quality of life of a subject having a peanut allergy. In certain embodiments, the disclosure provides methods for improving the quality of life of a subject having a peanut allergy by administering a peanut composition according to an oral immunotherapy schedule. In certain embodiments, the disclosure provides methods for improving the quality of life of a subject having a peanut allergy by informing the subject they are to be, or are being, administered a peanut composition according to an oral immunotherapy schedule.

Abstract: An herbal formula used for preparing a pharmaceutical composition for preventing and treating metabolic syndrome is provided. The herbal formula includes Rehmanniae radix preparata, Cornus officinalis, Dioscorea polystachya, Alisma plantago-aquatica, Paeonia suffruticosa, Poria cocos, Aconitum carmichaeli, and Cinnamomum cassia.

Abstract: The present disclosure provides a method for regulating expression of PDGFC, FGF2, IGF1R, PTGIS, NOS3, EDN1, PLAT, PROC, VWF, F3, SERPINE1, IL-8, ICAM1, VCAM1, and CASP8 genes, including administering to a subject in need thereof a composition including an effective amount of a plant extract, wherein the plant extract includes at least one combination selected from the group consisting of a grape seed extract and a Four seasons spring tea extract, a black tea extract and a spinach extract, the grape seed extract and the spinach extract, the grape seed extract and a green coffee bean extract, a red wine extract and a Pu-erh tea extract, and the grape seed extract and the Pu-erh tea extract.

Abstract: The present invention provides a composition containing plant extracts and the use thereof. Compared to a single plant extract, the combination of the plant extracts of the present invention can effectively enhance the synthesis of collagen. The plant extracts constituting the composition include: an extract of grape seed, black tea, green tea, red wine, citrus, spinach, green coffee bean, blueberry, Pu-erh tea, or Four Seasons Spring tea.

Abstract: Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.

Abstract: Disclosed is the use of a KOR agonist in combination with a MOR agonist in preparing a drug for treating pain. The KOR agonist is selected from a compound as shown in the general formula (I), and the MOR agonist is selected from a compound as shown in the general formula (II), wherein the definitions of each substituent in the general formula (I) and (II) are the same as defined in the description.

Abstract: Disclosed are methods for treating a patient suffering from (i) a cognitive, neurological or psychological disease or disorder; and (ii) a sleep disorder comprising the step of administering to said patient a therapeutically effective amount of an N-Methyl-D-aspartic acid (NMDA) receptor partial agonist, in particular rapastinel or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.

Abstract: Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.

Abstract: Provided herein are methods and compositions for the treatment of Gram positive bacterial infections. The infection in some embodiments, is a pulmonary infection. The method for treating the bacterial infection, comprises in one embodiment, administering to a patient in need thereof, a composition comprising an effective amount of a compound a glycopeptide derivative of Formula (I) or (II), or a pharmaceutically acceptable salt of Formula (I) or (II).

Abstract: Lipid-based drug delivery vehicles (including liposomal nanoparticles) are described which include antibiotic(s) for the FIG. 5 treatment of infections, such as Methicillin-Resistant Staphylococcus (S.) aureus (MRSA) infections and Methicillin-Susceptible S. aureus (MSSA) infections. These drug delivery vehicles have high drug-loading, do not accumulate in the liver, and can optionally include one or more targeting ligands.

Abstract: The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, cirrhosis, or hepatocellular carcinoma.

Abstract: The invention relates to the field of medicine and microbiology, more specifically to means and methods for the treatment of infections caused by Gram-negative pathogens, in particular those showing or being prone to developing drug resistance. Provided is an admixture of (i) an inner membrane acting compound having membrane-permeating activity and/or lipid H binding activity; and (ii) one or more antimicrobial peptide(s) selected from the group consisting of RRLFRRIRWL-NH2 (GNP-6); GNNRPVYIPQPRPPHPRL (GNP-1); RIWVIWRR—NH2 (GNP-5); GIGKHVGKALKGLKGLLKGLGEC (GNP-7); and Xi X2IVQRIKKWLX3-NH2, wherein Xi is absent or K; X2 is R, K or A; and X3 is absent or R; wherein said one or more antimicrobial peptide(s) may comprise or consist of D- or L-amino acids.

Abstract: The present disclosure is directed to methods and compositions for inhibiting a cancer cell using nucleic acid sequences encoding elephant p53 or elephant p53 amino acid sequences.

Abstract: Disclosed are the use of neuregulin proteins in preparing a medicine for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, and a method for using the medicine. Also provided in the present invention is a method for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, comprising using the medication containing the neuregulin proteins in a special population having the disease or being at risk of having the disease.

Abstract: This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.